Renalytix PLC
25 September 2026
Renalytix plc
(“Renalytix” or the “Company”)
Investor Presentations
LONDON and NEW YORK, 25 September 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that it will host a live online investor presentation next week and will be presenting at the MelloLondon2026 event in November. Details of the two events are below.
On-line presentation: Investor Meet Company
James McCullough, Chief Executive Officer, will provide a live presentationvia Investor Meet Company at 16:00 BST onTuesday, 29 September 2026. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meetRenalytix Plcvia:
https://www.investormeetcompany.com/renalytix-plc-1/register.
Investors who already followRenalytix plcon the Investor Meet Company platform will automatically be invited.
In-person presentation: MelloLondon2026
Renalytix will also bepresenting at theMelloLondon2026investor event onTuesday 17 November 2026. The event is taking place at The Clayton Hotel & Conference Centre, Chiswick High Road, London, W4 5RY.
Renalytix will present twice during the event. There will also be opportunity to interact with the management team at the Company’s exhibitor stand. For further informationandtickets for theMelloLondon2026 conference, please visit the eventwebsite athttps://www.melloevents.com/mellolondon2026.
For further information, please contact:
|
Renalytix plc |
||
|
James McCullough, CEO |
Via Walbrook PR |
|
|
|
|
|
|
SP Angel Corporate Finance LLP (Nominated Adviser, Joint Broker) |
Tel: +44 (0)20 3470 0470 |
|
|
David Hignell/ Jen Clarke (Corporate Finance) |
|
|
|
Vadim Alexandre (Corporate Broking) |
|
|
|
|
|
|
|
Oberon Capital(Joint Broker) |
Tel: +44 (0)20 3179 5300 |
|
|
Mike Seabrook / Nick Lovering |
|
|
|
|
|
|
|
Walbrook PR Limited |
Tel: +44 (0)20 7933 8780or renalytix@walbrookpr.com |
|
|
Paul McManus / Alice Woodings |
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
|
About kidneyintelX.dkd and RenalytixTM (www.kidneyintelx.com and www.renalytix.com)
RenalytixTM (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabledin vitrodiagnostics company dedicated to optimizing kidney disease management through precision-based care intervention. It’s KidneyIntelX™ technology and data-driven insights help clinical teams understand patient level of risk for progressive decline in kidney function in the earliest stages of diabetic kidney disease. This enables clinicians to focus resources and guideline-recommended treatment, providing the best chance for improving kidney and overall renal-cardio-metabolic outcomes.
Unrecognized and uncontrolled diabetic kidney disease remains one of the largest barriers to reducing suffering and controlling cost in the United States’ and the United Kingdom’s medical systems, affecting approximately 15 million and 8 million people, respectively.
RenalytixTM has been granted FDA authorization and Medicare reimbursement forkidneyintelX.dkdwhich is offered commercially throughout the United States. For more information about the kidneyintelX.dkd test, visit www.kidneyintelx.com.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.